Wellington Management Group LLP Sells 28,360 Shares of CareDx, Inc (NASDAQ:CDNA)

Wellington Management Group LLP cut its stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 14.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,362 shares of the company's stock after selling 28,360 shares during the period. Wellington Management Group LLP owned about 0.30% of CareDx worth $3,540,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CDNA. Vanguard Group Inc. raised its holdings in shares of CareDx by 7.1% in the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after purchasing an additional 323,554 shares during the last quarter. Bamco Inc. NY increased its stake in CareDx by 17.6% in the 4th quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock valued at $47,258,000 after buying an additional 330,627 shares during the last quarter. Fred Alger Management LLC lifted its position in shares of CareDx by 7.3% during the 4th quarter. Fred Alger Management LLC now owns 1,613,992 shares of the company's stock worth $34,556,000 after buying an additional 110,471 shares in the last quarter. Invesco Ltd. boosted its stake in shares of CareDx by 3.5% in the 4th quarter. Invesco Ltd. now owns 1,514,850 shares of the company's stock worth $32,433,000 after buying an additional 51,160 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of CareDx by 15.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock worth $30,663,000 after buying an additional 196,298 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group lowered their target price on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, Stephens restated an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

Insider Buying and Selling at CareDx

In other news, Director Peter Maag sold 13,281 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the sale, the director now directly owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. This represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William A. Hagstrom sold 30,000 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total transaction of $523,500.00. Following the transaction, the director now directly owns 53,979 shares of the company's stock, valued at approximately $941,933.55. This represents a 35.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 89,382 shares of company stock valued at $1,458,009 in the last 90 days. 4.90% of the stock is currently owned by company insiders.

CareDx Trading Up 4.1%

Shares of CDNA stock traded up $0.76 on Friday, hitting $19.52. 904,107 shares of the stock were exchanged, compared to its average volume of 906,933. The firm's 50 day moving average is $17.28 and its two-hundred day moving average is $20.43. CareDx, Inc has a one year low of $13.18 and a one year high of $34.84. The firm has a market capitalization of $1.09 billion, a PE ratio of -7.23 and a beta of 2.27.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company's revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) earnings per share. On average, sell-side analysts expect that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.